PMID- 29082740
OWN - NLM
STAT- MEDLINE
DCOM- 20180815
LR  - 20210816
IS  - 1130-0108 (Print)
IS  - 1130-0108 (Linking)
VI  - 109
IP  - 12
DP  - 2017 Dec
TI  - Methylation status of the estrogen receptor 1 promoter predicts poor prognosis of 
      acute-on-chronic hepatitis B liver failure.
PG  - 818-827
LID - 10.17235/reed.2017.4426/2016 [doi]
AB  - BACKGROUND: Acute-on-chronic hepatitis B liver failure (ACHBLF) is an acute 
      deteriorating liver disease and rapidly progresses to multiple organ failure. 
      There is currently no adequate accurate predictive models of ACHBLF prognosis. 
      AIMS: To identify the methylation frequency of the estrogen receptor 1 (ESR1) 
      promoter in ACHBLF and analyze the associated prognostic significance. METHODS: 
      Methylation-specific PCR (MSP) was used to determine the methylation frequency of 
      the ESR1 promoter in peripheral blood mononuclear cells from a training and 
      validation cohort of patients. The training cohort included 113 patients with 
      ACHBLF, 73 with chronic hepatitis B (CHB) and 40 healthy controls (HCs). The 
      validation cohort consisted of 37 patients with ACHBLF. Another 18 patients with 
      pre-ACHBLF who progressed to ACHBLF were used to dynamically evaluate ESR1 
      promoter methylation changes associated with a severe clinical condition. 
      RESULTS: Death from ACHBLF was associated with hyperbilirubinemia, a higher score 
      in the model for end-stage liver disease (MELD), a higher incidence of hepatic 
      encephalopathy (HE) and an increased frequency of ESR1 promoter methylation 
      during the 28 day follow-up. HE, MELD score and ESR1 promoter methylation were 
      the independent risk factors associated with 28-day mortality from ACHBLF. The 
      frequency of ESR1 promoter methylation was significantly higher than in patients 
      with CHB and HCs. Albumin and the MELD score were significantly associated with 
      ESR1 promoter methylation. Moreover, ESR1 promoter methylation frequency 
      increased with ACHBLF progression. More importantly, ESR1 promoter methylation 
      was an independent risk factor and had a high value to predict 28-day mortality 
      from ACHBLF. CONCLUSIONS: Abnormal ESR1 methylation could be a prognostic 
      biomarker for ACHBLF.
FAU - Fan, Xiao-Peng
AU  - Fan XP
AD  - Department of Hepatology, Qilu Hospital of Shandong University.
FAU - Dou, Cheng-Yun
AU  - Dou CY
AD  - Department of Hepatology, Qilu Hospital of Shandong University.
FAU - Fan, Yu-Chen
AU  - Fan YC
AD  - Department of Hepatology, Qilu Hospital of Shandong University;Hepatology 
      Institute of Shandong University.
FAU - Cao, Chuang-Jie
AU  - Cao CJ
AD  - Department of Pathology, the first affiliated hospital of Sun Yat-san University.
FAU - Zhao, Ze-Hua
AU  - Zhao ZH
AD  - Department of Hepatology, Qilu Hospital of Shandong University.
FAU - Wang, Kai
AU  - Wang K
AD  - Department of Hepatology, Qilu Hospital of Shandong University, China.
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Rev Esp Enferm Dig
JT  - Revista espanola de enfermedades digestivas
JID - 9007566
RN  - 0 (ESR1 protein, human)
RN  - 0 (Estrogen Receptor alpha)
SB  - IM
MH  - Acute-On-Chronic Liver Failure/*genetics/therapy
MH  - Adult
MH  - Cohort Studies
MH  - DNA Methylation
MH  - Estrogen Receptor alpha/*genetics
MH  - Female
MH  - Hepatitis B, Chronic/*genetics/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
EDAT- 2017/10/31 06:00
MHDA- 2018/08/16 06:00
CRDT- 2017/10/31 06:00
PHST- 2017/10/31 06:00 [pubmed]
PHST- 2018/08/16 06:00 [medline]
PHST- 2017/10/31 06:00 [entrez]
AID - 10.17235/reed.2017.4426/2016 [doi]
PST - ppublish
SO  - Rev Esp Enferm Dig. 2017 Dec;109(12):818-827. doi: 10.17235/reed.2017.4426/2016.